137 related articles for article (PubMed ID: 6383499)
1. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.
Parkman R; Rappeport JM; Hellman S; Lipton J; Smith B; Geha R; Nathan DG
Blood; 1984 Oct; 64(4):852-7. PubMed ID: 6383499
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
Hartsell WF; Czyzewski EA; Ghalie R; Kaizer H
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):69-73. PubMed ID: 7536723
[TBL] [Abstract][Full Text] [Related]
3. A comparison between regimens containing chemotherapy alone (busulfan and cyclophosphamide) and chemotherapy (V. RAPID) plus total body irradiation on marrow engraftment following allogeneic bone marrow transplantation.
Reynolds M; McCann SR
Eur J Haematol; 1989 Oct; 43(4):314-20. PubMed ID: 2684682
[TBL] [Abstract][Full Text] [Related]
4. Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.
Spitzer TR; Peters C; Ortlieb M; Tefft MC; Torrisi J; Cahill R; Gadner H; Urban C; Deeg HJ
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):39-44. PubMed ID: 8175444
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Blume KG; Kopecky KJ; Henslee-Downey JP; Forman SJ; Stiff PJ; LeMaistre CF; Appelbaum FR
Blood; 1993 Apr; 81(8):2187-93. PubMed ID: 8471778
[TBL] [Abstract][Full Text] [Related]
6. Risk factors in interstitial pneumonitis following allogenic bone marrow transplantation.
Pino y Torres JL; Bross DS; Lam WC; Wharam MD; Santos GW; Order SE
Int J Radiat Oncol Biol Phys; 1982 Aug; 8(8):1301-7. PubMed ID: 6754666
[TBL] [Abstract][Full Text] [Related]
7. Recipient preparation for bone marrow transplantation. I. Efficacy of total-body irradiation and busulfan.
Mauch P; Down JD; Warhol M; Hellman S
Transplantation; 1988 Aug; 46(2):205-10. PubMed ID: 3043777
[TBL] [Abstract][Full Text] [Related]
8. Late tissue-specific toxicity of total body irradiation and busulfan in a murine bone marrow transplant model.
Down JD; Berman AJ; Warhol M; Van Dijken PJ; Ferrara JL; Yeap B; Hellman S; Mauch PM
Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):109-16. PubMed ID: 2663795
[TBL] [Abstract][Full Text] [Related]
9. High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies.
Blume KG; Forman SJ
Blut; 1987 Jul; 55(1):49-53. PubMed ID: 3300817
[TBL] [Abstract][Full Text] [Related]
10. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
Demirer T; Buckner CD; Appelbaum FR; Lambert K; Bensinger WI; Clift R; Storb R; Slattery JT
Bone Marrow Transplant; 1996 Mar; 17(3):341-6. PubMed ID: 8704684
[TBL] [Abstract][Full Text] [Related]
11. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy.
Van der Jagt RH; Appelbaum FR; Petersen FB; Bigelow CL; Fisher LD; Schoch GH; Buckner CD; Sanders JE; Storb R; Sullivan KM
Bone Marrow Transplant; 1991 Sep; 8(3):211-5. PubMed ID: 1958901
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies.
Lynch MH; Petersen FB; Appelbaum FR; Bensinger WI; Clift RA; Storb R; Sanders JE; Hansen JA; Buckner CD
Bone Marrow Transplant; 1995 Jan; 15(1):59-64. PubMed ID: 7742756
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
Bunin N; Aplenc R; Kamani N; Shaw K; Cnaan A; Simms S
Bone Marrow Transplant; 2003 Sep; 32(6):543-8. PubMed ID: 12953124
[TBL] [Abstract][Full Text] [Related]
14. Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Domenech J; Linassier C; Gihana E; Dayan A; Truglio D; Bout M; Petitdidier C; Delain M; Petit A; Brémond JL
Blood; 1995 Jun; 85(11):3320-7. PubMed ID: 7756665
[TBL] [Abstract][Full Text] [Related]
15. Correction of congenital bone marrow disorders by allogeneic bone marrow transplantation following preparation with anti-human thymocyte serum and total body irradiation.
Rappeport JM; Parkman R; Belli JA; Cassidy JR; Levey R
Transplant Proc; 1981 Mar; 13(1 Pt 1):241-4. PubMed ID: 7022831
[No Abstract] [Full Text] [Related]
16. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.
Ringdén O; Remberger M; Ruutu T; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Mellander L; Ljungman P; Jacobsen N
Blood; 1999 Apr; 93(7):2196-201. PubMed ID: 10090927
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia.
Dusenbery KE; Daniels KA; McClure JS; McGlave PB; Ramsay NK; Blazar BR; Neglia JP; Kersey JH; Woods WG
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):119-28. PubMed ID: 7995742
[TBL] [Abstract][Full Text] [Related]
18. Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Inoue T; Ikeda H; Yamazaki H; Tang JT; Song C; Teshima T; Murayama S; Ohtani M; Shibata H; Masaoka T
Strahlenther Onkol; 1993 Apr; 169(4):250-5. PubMed ID: 8488461
[TBL] [Abstract][Full Text] [Related]
19. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Schultz KR; Ratanatharathorn V; Abella E; Eisenbrey AB; Karanes C; Lum LG; de Planque MM; Uberti JP; Ravindranath Y; Sensenbrenner LL
Bone Marrow Transplant; 1994 Jun; 13(6):817-22. PubMed ID: 7920320
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
